Summary
Cyclosporine has reached the approved stage (maximum clinical phase 4) for at least one indication, so its use in Polycystic Kidney Disease (ADPKD) would be drug repurposing rather than first-in-human development. This does not mean it is approved for Polycystic Kidney Disease (ADPKD). ClinicalTrials.gov lists 1 registered trial linking Cyclosporine to Polycystic Kidney Disease (ADPKD): 1 is active or not yet recruiting. The most advanced is Phase 1 (NCT07565441). It plans or enrolled 112 participants. Registered activity dates to 2026. The literature layer holds 1 publication for this pair: 1 Cochrane review. The dated items are from 2025. Because at least one synthesis-level source exists (systematic review, meta-analysis or Cochrane review), this pair has been assessed beyond single studies, although the synthesis may concern a different indication.
The RepurpOS disease-intelligence file for Polycystic Kidney Disease ranks 50 candidate therapeutics from Open Targets, ChEMBL, DGIdb and PubMed; only a minority carry direct clinical evidence, and this page covers one of those. Spontaneous remission context recorded for the condition: Progressive; GFR decline averages 4-5 mL/min/year in Mayo Class 1C-1E; renal failure by 60-70 years in 50% without treatment; spontaneous stabilisation rare.
Evidence table
| Evidence tier | A · Strong |
|---|---|
| Evidence score | 27.5 (trials 2.5, literature 5.0, tier 15, approved bonus 5.0) |
| Registered trials | 1 total: 0 recruiting, 1 active / not yet recruiting, 0 completed, 0 other |
| Linked publications | 1 (1 Cochrane review) |
| Agent type | Drug (Small molecule) |
| Development stage (any indication) | Approved |
| Mechanism / class | Not recorded |
| Data sources | DGIdb |
| Linked via biomarker / target | AGTR1 |
How the evidence score is calculated
- Each registered trial scores by status (recruiting / active / enrolling 3, completed 2.5, not yet recruiting 2, unknown 1, terminated / withdrawn / suspended 0.5) plus a phase bonus (phase 3-4 +2, phase 2 +1, phase 1 +0.5). The trial component is capped at 30.
- Each literature item scores by design (Cochrane review 5, meta-analysis 4, systematic review 3, RCT 3, clinical trial publication 2, curated reference 1.5, other PubMed record 1). The literature component is capped at 30.
- The existing evidence tier adds 15 (A / Strong), 10 (B / Moderate), 5 (C / Preliminary) or 0 (D / Anecdotal).
- Agents approved for any indication (max clinical phase 4) add 5, because an approved agent has an established safety profile that lowers the barrier to repurposing trials.
- The score ranks what has been studied, not what works. It does not read effect sizes or directions of effect.
Registered clinical trials
| NCT ID | Title | Status | Phase | Enrolment |
|---|---|---|---|---|
| NCT07565441 | Drug-Drug Interactions of JMKX003142 in Healthy Participants 2026 | not yet recruiting | Phase 1 | 112 |
Published literature
- Cochrane review [Risk factors for new-onset diabetes after transplantation in kidney transplant recipients: own data and meta-analysis]Novikova MS, Minushkina LO, Kotenko ON et al. · Terapevticheskii arkhiv · 2025 · PMID 40237731
Mechanism and notes
No mechanism of action is recorded for this pair in the source databases.
OSMF's existing evidence tier for this pair is A (Strong), derived from the strength of the disease association recorded in DGIdb, in this case via the biomarker or target AGTR1. The tier describes how well the drug-disease link is documented, not how well the drug works.
Frequently asked questions
Is Cyclosporine approved for Polycystic Kidney Disease (ADPKD)?
Cyclosporine has reached the approved stage (maximum clinical phase 4) for at least one indication, so its use in Polycystic Kidney Disease (ADPKD) would be drug repurposing rather than first-in-human development. This does not mean it is approved for Polycystic Kidney Disease (ADPKD). Approval status for the specific indication should always be confirmed with the relevant regulator and prescribing information.
Is Cyclosporine in clinical trials for Polycystic Kidney Disease (ADPKD)?
ClinicalTrials.gov lists 1 registered trial linking Cyclosporine to Polycystic Kidney Disease (ADPKD): 1 is active or not yet recruiting. The most advanced is Phase 1 (NCT07565441). It plans or enrolled 112 participants. Registered activity dates to 2026.
What does the evidence show for Cyclosporine in Polycystic Kidney Disease (ADPKD)?
Trials of Cyclosporine in Polycystic Kidney Disease (ADPKD) are registered but none has completed, so there is no outcome evidence from those studies yet; the record is a signal of research interest. OSMF's existing evidence tier for this pair is A (Strong), derived from the strength of the disease association recorded in DGIdb, in this case via the biomarker or target AGTR1. The tier describes how well the drug-disease link is documented, not how well the drug works.
Cite this page
Data: ClinicalTrials.gov, PubMed, Open Targets, ChEMBL, DGIdb and the OSMF therapeutic agent database. Last updated 2026-07-06. Page built 2026-10-07.